Living Cell Technologies Limited
LVCLY · OTC
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.03 | 0.10 | 0.29 |
| FCF Yield | 0.00% | -8.38% | -5.43% | -8.33% |
| EV / EBITDA | 0.00 | -7.32 | -33.38 | -11.56 |
| Quality | ||||
| ROIC | 0.00% | -41.48% | -21.76% | -47.96% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.70 | 1.04 | 0.88 | 1.18 |
| Growth | ||||
| Revenue 3-Year CAGR | -63.39% | -67.36% | -52.63% | -48.02% |
| Free Cash Flow Growth | 0.00% | -20.96% | 27.65% | 20.43% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 3.15 | 12.21 | 3.32 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 205.46 | 0.00 |